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Abstract
Background
Myasthenia gravis (MG) is an autoimmune disease in which 90% of patients have autoanti-
bodies against the muscle nicotinic acetylcholine receptor (AChR), while autoantibodies to
muscle-specific tyrosine kinase (MuSK) have been detected in half (5%) of the remaining
10%. Recently, the low-density lipoprotein receptor-related protein 4 (LRP4), identified as
the agrin receptor, has been recognized as a third autoimmune target in a significant portion
of the double sero-negative (dSN) myasthenic individuals, with variable frequency depend-
ing on different methods and origin countries of the tested population. There is also convinc-
ing experimental evidence that anti-LRP4 autoantibodies may cause MG.
Methods
The aim of this study was to test the presence and diagnostic significance of anti-LRP4
autoantibodies in an Italian population of 101 myasthenic patients (55 dSN, 23 AChR posi-
tive and 23 MuSK positive), 45 healthy blood donors and 40 patients with other neurological
diseases as controls. All sera were analyzed by a cell-based antigen assay employing
LRP4-transfected HEK293T cells, along with a flow cytofluorimetric detection system.
Results
We found a 14.5% (8/55) frequency of positivity in the dSN-MG group and a 13% frequency
of co-occurrence (3/23) in both AChR and MuSK positive patients; moreover, we report a
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younger female prevalence with a mild form of disease in LRP4-positive dSN-MG
individuals.
Conclusion
Our data confirm LRP4 as a new autoimmune target, supporting the value of including anti-
LRP4 antibodies in further studies on Myasthenia gravis.
Introduction
Myasthenia gravis (MG) is a disorder of neuromuscular transmission characterized by fluctuat-
ing muscle weakness and abnormal fatigability. Apart from rare cases of genetically determined
myasthenic syndromes, the majority (up to 85%) of patients have auto-antibodies (auto-abs)
directed against the nicotinic acetylcholine receptor (AChR) [1,2]; low affinity abs against
AChR have been found in 5% of the remaining MG patients [3,4]; up to 50% of patients with-
out anti-AChR abs display immunoreactivity to muscle-specific tyrosine kinase (MuSK) [5–7].
Both target antigens are membrane proteins that play essential roles at the neuromuscular
junction (NMJ): the high concentration of AChRs at the top of postsynaptic folds is crucial for
an efficient signal transmission from nerve to muscle. On the other hand, MuSK is essential for
formation, maintenance, and regeneration of postsynaptic specializations, including AChR
clustering [8]: neuronally-released agrin binds to the low-density lipoprotein receptor-related
protein-4 (LRP4) and forms a complex that, in turn, activates MuSK [9,10]. LRP4 is located at
the postsynaptic membrane of the NMJ and also on motor neurons in the brain and spinal
cord [11–13].
Considering its critical role in AChR clustering, its large extracellular domain and the spatial
proximity with MuSK, LRP4 was proposed as a possible autoantigen in patients with MG with-
out detectable antibodies to previously identified components of the NMJ [14]. In fact, a pro-
portion of patients without anti-AChR or anti-MuSK abs, and therefore classified as double-
seronegative (dSN-MG), was found to harbor abs against LRP4 [15–19].
While anti-AChR abs accelerate degradation and activate complement-mediated destruc-
tion of the postsynaptic membrane, anti-MuSK abs appear to interfere with MuSK signaling
and cause fragmentation of AChR clusters [20,21]. Further studies also indicate that anti-
MuSK abs block the binding of the collagenic tail of acetylcholinesterase (AChE) to MuSK [22]
and, accordingly, anti-AChE abs have been detected in patients with the pure ocular form of
MG [23]. Even though LRP4 (along with MuSK) is not directly involved in neuromuscular
transmission, there are convincing evidences that anti-LRP4 abs are pathogenic for MG. Schen
and coworkers demonstrated that active immunization with the extracellular domain of LRP4
or passive transfer of IgGs purified from LRP4-immunized rabbits induced MG-associated
symptoms and compromised neuromuscular transmission in mice. This effect was probably
achieved thorough decreased cell surface LRP4 levels, inhibition of agrin-induced MuSK acti-
vation and AChR clustering and complement activation [24]. Very recently, Barik and cowork-
ers showed that LRP4 ablation in mice led to loss of synaptic agrin, suggesting that LRP4 is
essential to maintain the structural and functional integrity of the NMJ through the regulation
of synaptic agrin stability [25]. Taken together, these evidences support the view that NMJ
development during synaptogenesis, as its plasticity or function in adulthood, requires ongoing
MuSK activation following agrin binding to LRP4.
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Since diagnosis and management for dSN-MG patients can be puzzling, ascertaining the
presence of autoantibodies against alternative protein targets could be of help in orienting clini-
cal decisions.
In this study we tested sera from 101 MG Italian patients and from 45 healthy blood donors
(HBD) and 40 patients with other neurological diseases (OND) as controls, employing a cell-
based antigen assay (CBA) along with a cytofluorimetric detection system. Our data confirm
LRP4 as a novel auto-antigen in MG patients; moreover, our results indicate that autoantibod-
ies against LRP4 may coexist with anti-AChR and anti-MuSK abs suggesting new perspectives
in MG-patients management.
Materials and Methods
Sera from MG patients and controls
The study included 101 Italian myasthenic patients seen at two distinct Hospitals in Rome
(Gemelli Hospital at “Università Cattolica”, Department of Neuroscience, and S. Andrea Hos-
pital at “La Sapienza” University, Neuromuscular Diseases Unit). All clinical investigations
have been conducted according to the principles expressed in the Declaration of Helsinki.
Samples were collected according to the guidelines of a research study approved from the
“Comitato Etico dell’Università Cattolica del Sacro Cuore” (Catholic University Ethical Com-
mittee; P/529/CE/2011) with written informed consent. All samples were anonymized. The
participant consents were recorded in Catholic University laboratories.
All patients had generalized MG, as defined by the Myasthenia Gravis Foundation of Amer-
ica (MGFA) classification [26] (i.e. a disease affecting muscles distinct from ocular muscles,
although ocular muscle weakness could be associated).
Anti-AChR and anti-MuSK abs were tested on the basis of standard assay (radioimmuno-
precipitation using 125I α-bungarotoxin-AChR complexes or 125I-labeled recombinant human
MuSK protein, respectively). We screened for anti-LRP4 immunoreactivity 55 sera from dSN-
patients, 23 sera from AChR-positive and 23 from MuSK-positive patients. Sera from 45 HBD
were analyzed as controls together with 40 OND: 11 polymyositis (PM), 10 mitochondrial
myopathies (MM), 9 multiple sclerosis (MS) and 10 amyotrophic lateral sclerosis (ALS).
Cell culture and transfection
Mammalian HEK293T cells (ATCC CRL-3216) were cultured in DMEM (EuroClone) plus
10% FCS (Sigma-Aldrich), 1% antibiotics, 1% glutamine (Sigma-Aldrich), 1% non-essential
aminoacids (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich) and maintained in a
humidified incubator at 37°C with 5% CO2.
Constructs encoding full-length (fl) rat LRP4 and extracellular domain (ecto)-LRP4 in
pcDNA3.1-Myc/His were prepared as previously described [9].
1μg of pcDNA3.1-LRP4fl-myc/His or 1μg of pcDNA3.1-LRP4ecto-myc/His were stably
transfected in HEK293T cells (3 x 105 in six-well plates) using the EFFECTENE reagent (Qia-
gen) according to manufacturer’s recommendations. We exposed un-transfected HEK293T
cells to different concentrations of neomycin (G418; Invitrogen) and identified 1,5 mg/ml as
the lethal dose, to which LRP4-transfected cells still survived after at least one week of expo-
sure. Then, we checked the expression of LRP4 testing the transfected cells with control anti-
LRP4 antiserum in cytofluorimetric assay. Instead, average transfection efficiency in LRP4fl-
transfected cells (30–35%) was determined using an equal amount of a plasmid encoding the
green fluorescent protein under the cytomegalovirus promoter (CMV-EGFP) and the percent-
age of fluorescent cells was determined 48 h after transfection by flow cytometry. To confirm
the transfection efficacy, we performed indirect immunofluorescence on transfected and
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untransfected HEK293T cells. Briefly, cells were fixed with methanol, washed three times with
cold PBS, blocked for 10 min at room temperature with PBS/BSA 5% and incubated for 30 min
at 4°C with serum samples from patients and healthy controls, at 1:100 dilution in PBS/BSA
0.1% (PBS-BSA). FITC conjugated anti-human IgG goat antiserum (AXA Diagnostics, Italy)
were added at a 1:100 dilution in PBS-BSA and the samples incubated for 30 min at 4°C. Cells
were examined on a Nikon Eclipse E600 fluorescence microscope. A representative immuno-
fluorescence is now displayed in S1 Fig, as additional material, which clearly shows much
stronger positivity of transfected cells compared to untransfected controls when challenged
with a previously validated anti-LPRP4 positive serum.
Similarly, transgene expression in LRP4ecto-transfected cells was verified by anti-Myc tag
western-blotting after at least 48 h from transfection. Having verified that LRP4 transfection
and selection had been successful, G418 concentration was reduced to 0,5–0,4 mg/ml; interest-
ingly, in this setting the expression of LRP4 was stable for no more than two weeks, likely due
to intrinsic toxicity of the gene product and selective overgrowth of LRP4 revertants or
untransfected cells.
Flow cytofluorimetric analysis
Fluorescence activated cell sorting (FACS) analysis was performed to detect binding of
patients’ IgG to the surface of LRP4fl-HEK293T and of parental untransfected HEK293T (that
do not express detectable levels of LRP4) cells as control, as previously described [27], with
minor modifications. We initially tested twenty sera on both mock-transfected and untrans-
fected cells, obtaining identical results. Based on this evidence, we kept on using untransfected
cells for the rest of the study.
Briefly, cells (1 x 105 per test) were resuspended in 50 μl PBS/BSA 0,1% (FACS buffer) and
incubated with primary antibodies: sera fromMG patients and HBD (dilution 1:5), or a com-
mercially available rabbit anti-LRP4 antiserum (Atlas Antibodies, Stockholm, Sweden; dilution
1:150); the latter antibody, that served as positive control, is specific for LRP4 and does not
cross-react with other members of the LRP protein family. Subsequently cell samples were
stained using the appropriate Alexa-conjugated goat anti-human IgG or goat anti-rabbit sec-
ondary antibody (594 and 488 respectively, dilution 1:100). Cells were then analyzed on a
FACScan (EpicsXL-MCL Coulter, Fullerton, California).
For each serum, the mean fluorescence intensity value (mean-F) on the LRP4fl-HEK293T
cells was compared to unspecific binding determined on the parental HEK293T cell population
to evaluate the antigen-specific immunoreactivity: positivity cut-off (1.5) was determined as
the mean + 2.5 SD of the ratios between the LRP4fl-mean-F and the corresponding parental-
mean-F of HBD sera (mean 1.1; SD 0.17). Each serum was tested at least two times with differ-
ent cellular transfections. The rabbit Anti-LRP4 antiserum was assayed in each test session as
quality control.
Immunoprecipitation and Blotting
LRP4ecto-HEK293T cells (transfected with the Myc-tagged LRP4 ectodomain-cDNA) were
employed to obtain a supernatant enriched of secreted soluble extracellular-LRP4. 48 hours (h)
after transfection, cells were serum-starved for 24 h before collection of supernatants. Aliquots
of one milliliter of supernatant were immunoprecipitated with 60 μl of human sera (mixtures
of equal volumes of two or more patients’/HBD controls’ sera) and 20 μl of protein A-Sephar-
ose for 3 h at 4°C, with continuous shaking. Immune-complexes were collected, washed three
times with PBS-Triton 1%, dissolved in Laemmli sample buffer 6x, separated by SDS-PAGE,
and transferred onto nitrocellulose (BioRad). Immunoblots were probed first with anti-c-Myc
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mAb (clone 9E10, Sc-40; Santa Cruz Biotechnology) (0,2 μg/ml), followed by horseradish per-
oxidase-conjugated secondary reagents (anti-mouse IgG, Amersham Biosciences, Inc.)
(1:5000). Aliquots of 500 μl of supernatants from LRP4ecto-HEK293T cells and from EGF-
P-HEK293T cells (transfected with a plasmid encoding the green fluorescent-not secreted- pro-
tein), as positive and negative control respectively, were treated with a methanol/chloroform
protocol [28] to recover proteins in dilute solutions. The protein concentrates were dissolved
in Laemmli sample buffer and subjected to SDS-PAGE and blotted alongside with immunopre-
cipitates. The Quantity-One software (Bio-Rad Laboratories) was used for image documenta-
tion and analysis.
Results
Production of recombinant LRP4
Following transfection with the pcDNA3.1-LRP4fl-myc/His plasmid, surface expression of
LRP4 in HEK-293T cells could be easily detected by FACS analysis using rabbit anti-LRP4 anti-
serum (Fig 1A).
Cells transfected with pcDNA3.1-LRP4ecto-myc/His produced a soluble form of the extra-
cellular domain, which could be precipitated from cell supernatants and detected by western
blotting using the anti-c-Myc mAb (Fig 1B).
FACS analysis of serum samples
Serum samples from 101 MG patients, from 45 HBD and from 40 OND patients were tested
on both parental un-transfected and LRP4fl-transfected HEK293T cells. While none of the
normal human sera (NHS) showed immunoreactivity, 14/101 patients sera showed a clear-cut
shift of mean fluorescence intensity (MFI transfected/MFI untransfected ratio> 1,5) (Fig 2).
Among these, 8 were from 55 dSN-MG patients (14.5%), 3 from 23 AChR-MG (13%) and 3
from 23 MuSK-MG patients (13%) (Table 1). Only one out of the additional 40 OND (1/11
PM) showed anti LRP4 immunoreactivity.
Fig 1. Expression of recombinant LRP4. (A) Flow cytofluorimetric analysis of parental untransfected
HEK293T cells labeled with the rabbit anti-LRP4 antiserum (shaded area), compared to LRP4fl-HEK293T
transfected cells (full line). (B) Precipitated supernatants from EGFP-HEK293T LRP4ecto-HEK293T cells
were analyzed by anti-c-Myc immunoblotting; the band corresponding to the ecto-LRP4-myc tag fusion
protein is indicated by arrow.
doi:10.1371/journal.pone.0135378.g001
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Immunoprecipitation and Blotting analysis
We were not able to immunoprecipitate the soluble, extracellular domain of LRP4 with sera
from individual patients. When, to increase sensitivity, we used pools of those sera that were
positive at FACS analysis, the MuSK-MG pool gave the best positive result; the two dSN-MG
pools were also able, although to a different extent (pool #1> pool #2), to immunoprecipitate
the antigen; instead the AChR pool did not precipitate any band of the expected size as assessed
by anti-myc tag immunoblotting (Fig 3).
Fig 2. Anti-LRP4 detection by FACS analysis. Each of 101 MG s and 85 control sera was tested on both
parental untransfected (shaded area) and on LRP4fl-HEK293T transfected cells (full line). None of the 45
NHS but only 14 MG sera showed a clear cut shift of mean fluorescence value with a ratio transfected/
untransfected > 1.5. We show the immunoreactivity of one NHS, one dSN-MG (sample#8), one AChR-MG
(sample#9) and one MuSK-MG serum (sample#14) (A,B,C,D respectively) as representative plots.
doi:10.1371/journal.pone.0135378.g002
Table 1. Anti-LRP4 immunoreactivity in 101 Italian myasthenic patients (MG) and controls.
Patients Number Anti-LRP4 immunoreactivity % (95% CI*)
Total MG 101 14 13.8 8–22
double seronegative 55/101 8 14.5 7.5–26.1
AChR positive 23/101 3 13 4.5–32.1
MuSK positive 23/101 3 13 4.5–32.1
HBD 45 0 0 0–7.9
PM 11 1 9 1.6–37.7
MM 10 0 0 0–27.7
MS 9 0 0 0–29.9
ALS 10 0 0 0–27.7
*:CI: Confidence Interval
doi:10.1371/journal.pone.0135378.t001
Anti-LRP4 Autoantibodies in Myasthenic Italian Patients
PLOS ONE | DOI:10.1371/journal.pone.0135378 August 18, 2015 6 / 12
Correlation with clinical characteristics
The whole MG population included 68 women and 33 men (ratio F:M: 2.06). The 14 LRP4 pos-
itive (pos) patients showed an increased female preponderance, 11 women and 3 men, when
compared to the 87 LRP4 negative (neg) patients, 57 women and 30 men: ratio F:M of 3.6 ver-
sus 1,9. When MG patients are subdivided in early onset (EO), according to age of onset 50
years, and late onset (LO), the whole MG population included 71 EO and 30 LO (ratio EO:LO:
2.3). We found that the LRP4-pos patients were younger, 11 EO and 3 LO, when compared to
the LRP4-neg patients, 60 EO and 27 LO: ratio EO:LO of 3.6 versus 2.22.
Considering only the 55 dSN-MG group (Table 2), there were 39 women and 16 men (ratio
F:M: 2.4). Among these, the 8 dSN/LRP4-pos patients displayed a female predominance
including 7 women and 1 men while the 47 dSN/LRP4-neg patients included 32 women and 15
men: ratio F:M of 7 versus 2.1. Considering age at onset, the whole dSN-MG group included 41
EO and 14 LO (ratio EO:LO: 2.9). Also in this case we found that the 8 dSN/LRP4-pos patients
Fig 3. Anti-LRP4 detection by immunoprecipitation of pools of sera. Supernatants from LRP4ecto
HEK293T cells were immune-precipitated with the indicated pools (p) of sera that scored positive at FACS
analysis: pool#1 and #2 from dSN-MG, Musk-MG pool and AChR-MG pool. Immuno-complexes were
subdued to western blotting and probed with anti-c-Myc. Aliquots of total supernatants from EGFP-HEK293T
and from LRP4ecto HEK293T cells were blotted alongside with immune-precipitates as negative and positive
control, respectively. The specific, uppermost band is pointed by the arrow.
doi:10.1371/journal.pone.0135378.g003
Table 2. Clinical correlates with and without anti-LRP4 antibodies in double seronegative myasthenic patients.
Double seronegative myasthenic patients LRP4-positive
(n°)
LRP4-negative
(n°)
Total
(n°)
Patients 8 47 55
Gender Female (F) 7 32 39
Males (M) 1 15 16
Age at onset Early (EO) 7 34 41
Late (LO) 1 13 14
Maximum MGFA I, IIA, IIB 6 22 28
IIIA, IIIB, IVA 2 20 22
IVB, V 0 5 5
Current therapy No therapy or symptomatic 1 13 14
Corticosteroid < 25mg/die 2 13 15
Corticosteroid > 25mg/die or other
immunosuppressors
5 21 26
Thymoma Yes 1 2 3
No 7 45 52
Therapy at the moment of sample
collection
Yes 0 33 33
No 8 14 22
doi:10.1371/journal.pone.0135378.t002
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displayed a younger age at onset predominance, including 7 EO and 1 LO while the 47 dSN/
LRP4-neg patients including 34 EO and 13 LO: ratio EO:LO of 7 versus 2.6.
Because of the small size of the population, the above differences are not statistically
significant.
The 8 dSN/LRP4-pos patients were without therapy at the moment of sample collection and
showed a less severe disease (Table 2): mild disease (class I, IIA, IIB) in 6 cases and moderate
disease (class IIIA, IIIB, IVA) in 2 cases, while no patient showed a severe disease (grade IVB,
V). No correlation with thymic pathology was found; only one patient displayed thymoma.
Discussion
Low-density lipoprotein receptor-related protein 4 (LRP4) has recently been identified as the
agrin receptor and has emerged as a third autoantigen in MG patients.
The detection of specific autoantibodies is a serological hallmark in the diagnosis of autoim-
mune diseases. We have developed a CBA in which the transfected autoantigen is expressed on
the surface of HEK293T cells or shedded in the medium as soluble protein. In the present
study, FACS analysis of membrane-directed immunoreactivity proved to be far more sensitive
than immunoprecipitation/immunoblotting of soluble LRP4, although we cannot rule out the
possibility that this difference is simply due to the low affinity of anti-LRP4 antibodies for pro-
tein-A sepharose, employed to precipitate the immune-complexes. Further, the soluble extra-
cellular domain of LRP4 can undergo conformational changes and no longer be recognized by
antibodies. Using FACS assay, we analyzed sera from 101 MG patients for the presence of
LRP4 abs.
Previous studies have identified LRP4 abs in 2–45% of dSN- MG patients of different eth-
nicities and countries of origin; in these reports, the co-occurrence of either AChR or MuSK
abs was found in some cases [15,17,18]. The different positivity rates could be ascribed to dif-
ferent methods: Higuchi and coworkers used an immunoprecipitation technique and a recom-
binant fusion protein made of the extracellular LRP4 domain fused to luciferase as antigen
[15]; Pevzner and coworkers used indirect immunofluorescence on LRP4-transfected cells
[17], while Zhang and coworkers used an ELISA with the recombinant extracellular domain of
LRP4 [18]. Zisimopoulou and coworkers screened a large dSN-MG sample collection, consist-
ing of 635 sera from 10 countries including Italy [29]. Through a CBA based on human LRP4
transfected-HEK293 cells, they found a positivity rate of 18.7%, with variations among differ-
ent populations (range 7–32.7%). Our results are in agreement with this last one: using a simi-
lar CBA, but with a different detection system, we found a 14.3% frequency of positive results
in an Italian series of 55 dSN-MG. Noteworthy, all the 8 LRP4-pos patients were without ther-
apy at the time of sample collection, suggesting that anti-LRP4 antibodies may be particularly
sensitive to the action of the therapy; if so, their frequency in the dSN-MG group could actually
be underestimated.
Interestingly, Zisimopoulou identified double positive (AChR/LRP4 and MuSK/LRP4) sera
among those from other countries, but not from Italy. In contrast we detected double positive
sera in our series: anti-LRP4 antibodies were found in 3/23 anti-AChR positive and in 3/23
anti-MuSK positive sera.
The detection of anti-LRP4 antibodies in patients' sera represents a significant advance in
the understanding and in the diagnosis of dSN-MG. In the most updated classification, Berrih-
Aknin and coworkers reported that approximately 90% of the total MG patients show anti-
AChR antibodies, that 5% of MG patients have anti-MuSK antibodies and ascribe anti-LRP4
antibodies to the 2% of the remaining 5% dSN-MG (range 12–50% of seronegative population)
[4]. In keeping with this classification, we here report anti-LRP4 antibodies in 14,3% of a
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population of 55 dSN-MG; thus, our contribution confirms the importance of anti-LRP4 detec-
tion as a useful diagnostic tool to decrease the percentage of MG (no longer “double” but “tri-
ple”) seronegative patients.
According to the presence of autoantibodies the MG forms are generally divided in different
subgroups with specific clinical features. AChR-MG displays three main clinical pictures: a)
the pure ocular form; b) the generalized EO form with female prevalence and follicular thymic
hyperplasia; c) the generalized LO form with an equal ratio of female to men and frequent asso-
ciation with thymoma [30]. MuSK-MG patients are typically female, and have a severe form of
the disease with frequently affected facial, bulbar and respiratory muscles, whereas ocular
symptoms and thymic abnormalities are rare [6, 31]. The clinical phenotype of the patients
presenting anti-LRP4 antibodies is not well defined. The most update classification reported a
younger female prevalence mainly without association with thymic pathology [4]. Accordingly,
albeit with the limitation of the small size of the screened population, we report a female preva-
lence with a mild form of disease in LRP4-dSN-MG patients.
Our results confirm anti-LRP4 antibodies as the third class of autoantibodies in MG as vali-
dated by recent literature [4, 29], although without association with a particular clinical picture.
Differently from anti-AChR and anti-MuSK abs, that seem to be mutually exclusive, the pres-
ent study confirm that anti-LRP4 abs could associate with anti-AChR or anti-MuSK abs.
During the current year new antibodies were indicated as putative auto-abs in MG: anti-
agrin and anti-cortactin (a protein that acts downstream from agrin/MuSK/LRP4, promoting
AChR clustering) [32–34]. These new data strengthen the hypothesis that auto-abs interfering
with agrin/LRP4/MuSK signaling at the NMJ can induce MG. However, in our opinion, anti-
agrin and anti-cortactin autoantibodies do not improve the diagnostic performance of MG. In
fact, as reported by Gasperi and coworkers, anti-agrin abs were not found in any double sero-
negative-MG sera but only in 5/54 MG-patients, who were also single positive for anti-AChR
or anti-MuSK auto-abs or double-seropositive for anti-MuSK/LRP4 abs [33]. Anti-cortactin
abs were identified by Gallardo and coworkers as potential autoantibodies in seronegative MG
but they were found in 12,5% of patients with other autoimmune disorders and also in 5,2% of
healthy controls [34].
LRP4 auto-abs seem to be related to MG disease: only one out of 40 OND patients (1/11
PM) showed anti LRP4 immunoreactivity.
With a frequency of 0% in our NHS group, we confirm Zisimopoulou’s data that found
anti-LRP4 antibodies in none of NHS series (0%). Nevertheless, while this manuscript was in
preparation, Tzartos and coworkers reported a high and persistent frequency of anti-LRP4 abs
in the sera (23.4%) and cerebrospinal fluid of patients with amyotrophic lateral sclerosis sug-
gesting that LRP4 autoimmune reactivity may be more widely related to damage of LRP4
expressing tissues such as NMJ but also motor neurons and brain. Anti-LRP4 abs in ALS could
represent the autoimmune component suggested for many years with a hypothetical (currently
not shown) pathogenic role in the neurodegenerative process [35]. In our 40 OND sera we
included also 10 ALS but we didn’t found anti-LRP4 antibodies in this series. Moreover, these
new data on the occurrence of anti-LRP4 abs in ALS should be confirmed and validated by fur-
ther studies.
In conclusion, based on ours and others’ results, we suggest that, in presence of a character-
istic clinical picture, pharmacological response and/or electromyography suggestive for MG,
without anti-AChR or anti-MuSK antibodies, the anti-LRP4 detection may represent an addi-
tional element in favor of the diagnosis. However, due to their limited specificity for MG and
in spite of the proven pathogenic role in experimental models, anti-LRP4 alone cannot be con-
sidered quite as indicative as anti-AChR and anti-MuSK abs in the diagnostic algorithm for the
disease. Moreover, further validated and standardized tests are critically needed to make the
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recognition and quantitation of LRP4 immunoreactivity more reliable and useful in the clinical
management of MG patients.
Supporting Information
S1 Dataset. The anonymous data set of MG patients.
(DOCX)
S2 Dataset. The anonymous data set of controls.
(DOCX)
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BSA 0.1% (PBS-BSA), for 30 min. FITC conjugated anti-human IgG goat antiserum (AXA
Diagnostics, Italy) were added at a 1:100 dilution in PBS-BSA and the samples incubated for 30
min at 4°C. Cells were examined on a Nikon Eclipse E600 fluorescence microscope.
(TIF)
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